July 20, 2011
-- Biomiga Diagnostics , a provider of rapid diagnostic testing solutions, announced today that it has signed purchasing agreement with Blue Cross Bio-Medical (Beijing) Co., a privately-held corporation high-tech enterprise specializing in rapid, diagnostic tests. Blue Cross pioneered the concept and technology of colloid gold rapid diagnostic tests. Its first generation IVD product, HCG pregnancy tests, revolutionized the entire IVD market in worldwide. Biomiga Diagnostics’
mission is to transform healthcare by providing patients and providers with quantitative and rapid point-of-care tests making personalized medicine a reality. This agreement with Blue Cross will strengthen and complement Biomiga Diagnostic’s product portfolio.
For additional information, please contact
Stephen Shi, PhD